CSIMarket
 


United Therapeutics Corporation  (UTHR)
Other Ticker:  
 
 

UTHR's Operating Income Growth by Quarter and Year

United Therapeutics's Operating Income results by quarter and year




UTHR Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 260.10 175.60 169.80 65.30
III Quarter September 327.00 314.30 228.70 221.10
II Quarter June 313.40 201.80 222.20 140.50
I Quarter March 284.40 288.00 -64.80 166.70
FY   1,184.90 979.70 555.90 593.60



UTHR Operating Income fourth quarter 2023 Y/Y Growth Comment
United Therapeutics Corporation achieved in the fourth quarter 2023, above Company average Operating Income rise of 48.12% year on year, to $ 260.10 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Operating Income growth. While United Therapeutics Corporation' s Operating Income jump of 48.12% ranks overall at the positon no. 577 in the fourth quarter 2023.

Explain Operating Income growth


UTHR Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 48.12 % 3.42 % 160.03 % 2.83 %
III Quarter September 4.04 % 37.43 % 3.44 % 20.56 %
II Quarter June 55.3 % -9.18 % 58.15 % -36.54 %
I Quarter March -1.25 % - - -
FY   20.95 % 76.24 % -6.35 % -

Financial Statements
United Therapeutics's fourth quarter 2023 Operating Income $ 260.10 millions UTHR's Income Statement
United Therapeutics's fourth quarter 2022 Operating Income $ 175.60 millions Quarterly UTHR's Income Statement
New: More UTHR's historic Operating Income Growth >>


UTHR Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -20.46 % -44.13 % -25.75 % -70.47 %
III Quarter September 4.34 % 55.75 % 2.93 % 57.37 %
II Quarter June 10.2 % -29.93 % - -15.72 %
I Quarter March 61.96 % 69.61 % - 162.52 %
FY (Year on Year)   20.95 % 76.24 % -6.35 % -




Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #42
Overall #577

Operating Income Y/Y Growth Statistics
High Average Low
292.8 % 17.05 % -123.29 %
(June 30. 2016)   (Dec 31 2019)
Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #42
Overall #577
Operating Income Y/Y Growth Statistics
High Average Low
292.8 % 17.05 % -123.29 %
(June 30. 2016)   (Dec 31 2019)

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

United Therapeutics's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
265.88 % 14 % -70.47 %
(Sep 30 2017)  


UTHR's IV. Quarter Q/Q Operating Income Comment
In the IV. Quarter 2023 United Therapeutics Corporation reported fall in Operating Income from the previous quarter by -20.46% to $ 260.10 millions, from $ 327.00 millions released in the previous quarter.

When you look into current shortcoming at the IV. Quarter, you should take into consideration, that usually IV. Quarter 2023 results appear to be softer in contrast to the preciding period

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Operating Income quarter on quarter growth. While United Therapeutics's Operating Income growth quarter on quarter, overall rank is 728.


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #57
Overall #728
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #57
Overall #728
Operating Income Q/Q Growth Statistics
High Average Low
265.88 % 14 % -70.47 %
(Sep 30 2017)  


UTHR's IV. Quarter Q/Q Operating Income Comment
In the IV. Quarter 2023 United Therapeutics Corporation disclosed fall in Operating Income sequentially by -20.46% to $ 260.10 millions, from $ 327.00 millions declared in the previous reporting period.

If you look into current slump at the IV. Quarter, you must assume, that commonly IV. Quarter Operating Income occur softer then in the third quarter

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Operating Income quarter on quarter growth. While United Therapeutics's Operating Income growth quarter on quarter, overall rank is 728.


United Therapeutics's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Operating Income 12 Months Ending $ 1,184.90 $ 1,100.40 $ 1,087.70 $ 976.10 $ 979.70
Y / Y Operating Income Growth (TTM) 20.95 % 12.99 % 22.45 % 7.42 % 76.24 %
Year on Year Operating Income Growth Overall Ranking # 122 # 160 # 74 # 151 # 1152
Seqeuential Operating Income Change (TTM) 7.68 % 1.17 % 11.43 % -0.37 % 0.6 %
Seq. Operating Income Growth (TTM) Overall Ranking # 577 # 810 # 475 # 319 # 576




Cumulative Operating Income growth Comment
United Therapeutics saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 20.95% year on year, to $ 1,185 millions if the fiscal year would have ended in Dec 31 2023.
United Therapeutics's trailing twelve months Operating Income growth was higher than company's average 17.05% and higher than 12.99% growth in Sep 30 2023.
But sequential growth rate was less at 7.68 % from $1100.4 millions reported in twelve months ending a quarter before.
We witness slowdown happening, more noticeable as we look at If you average sequential historic increase what is stronger at17.05% Olivia Jones published.
The growth was even more impressive from the previous reporting period showed at 7.68 % rise from $1100.4 millions in twelve months ending a quarter before.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 122, from total ranking in previous quarter at 160.

Operating Income TTM Q/Q Growth Statistics
High Average Low
292.8 %
17.05 %
-123.29 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 11
Overall # 122

Operating Income TTM Y/Y Growth Statistics
High Average Low
292.8 %
17.05 %
-123.29 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 42
S&P 500 # 577
Cumulative Operating Income growth Comment
United Therapeutics saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 20.95% year on year, to $ 1,185 millions if the fiscal year would have ended in Dec 31 2023.
United Therapeutics's trailing twelve months Operating Income growth was higher than company's average 17.05% and higher than 12.99% growth in Sep 30 2023.
But sequential increase was beneth at 7.68 % from $1100.4 millions recorded in twelve months ending a quarter before Olivia Jones added on.
There is drop-off developing, more noticeable observing the If you typical sequential Operating Income rise that is better at17.05% Olivia Jones wrote.
The growth was much higher from the previous reporting period clinched at 7.68 % increase from $1100.4 millions in twelve months ending a quarter before.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Operating Income growth. While Total ranking has impoved so far to 122, from total ranking in previous quarter at 160.

Operating Income TTM Q/Q Growth Statistics
High Average Low
292.8 %
17.05 %
-123.29 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 11
Overall # 122

Operating Income TTM Y/Y Growth Statistics
High Average Low
292.8 %
17.05 %
-123.29 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 42
S&P 500 # 577




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
UTHR's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for UTHR's Competitors
Operating Income Growth for United Therapeutics's Suppliers
Operating Income Growth for UTHR's Customers

You may also want to know
UTHR's Annual Growth Rates UTHR's Profitability Ratios UTHR's Asset Turnover Ratio UTHR's Dividend Growth
UTHR's Roe UTHR's Valuation Ratios UTHR's Financial Strength Ratios UTHR's Dividend Payout Ratio
UTHR's Roa UTHR's Inventory Turnover Ratio UTHR's Growth Rates UTHR's Dividend Comparisons



Companies with similar Operating Income fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2023
Elite Pharmaceuticals Inc 80.32%$ 80.320 millions
Dr Reddy s Laboratories Limited78.66%$ 78.663 millions
Electromed Inc 77.63%$ 77.630 millions
Eli Lilly And Company74.93%$ 74.935 millions
Dexcom Inc 72.97%$ 72.967 millions
Sotera Health Company72.89%$ 72.889 millions
Dariohealth Corp 57.77%$ 57.769 millions
Alcon inc 54.61%$ 54.613 millions
Stryker Corp54.42%$ 54.423 millions
Align Technology inc 52.27%$ 52.267 millions
Davita Inc 52.16%$ 52.158 millions
Healthcare Services Group Inc 51.40%$ 51.399 millions
Tactile Systems Technology Inc 50.32%$ 50.318 millions
Viemed Healthcare Inc 49.66%$ 49.660 millions
United Therapeutics Corporation48.12%$ 48.121 millions
Lemaitre Vascular Inc 46.49%$ 46.491 millions
Neurocrine Biosciences Inc 45.36%$ 45.358 millions
Boston Scientific Corporation45.27%$ 45.274 millions
Msa Safety Incorporated44.79%$ 44.789 millions
Corcept Therapeutics Inc40.76%$ 40.757 millions
Powerup Acquisition Corp 39.00%$ 38.999 millions
Tenet Healthcare Corp37.13%$ 37.127 millions
Chemed Corporation36.97%$ 36.971 millions
Abbott Laboratories36.50%$ 36.503 millions
Nature s Sunshine Products inc 36.49%$ 36.490 millions
Halozyme Therapeutics Inc 35.60%$ 35.601 millions
Catalyst Pharmaceuticals Inc 35.36%$ 35.359 millions
Iqvia Holdings Inc 32.19%$ 32.190 millions
Select Medical Holdings Corp31.53%$ 31.531 millions
Tenax Therapeutics Inc 30.78%$ 30.780 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com